Loading search results
Sponsor study identifier
Secondary identifiers
OTHER · NMRC IRB
interventional
16
1 country
2
Study Start
January 2010
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
December 2010
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
September 2011
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
The goal of this research is to continue to develop a model of infection with Campylobacter jejuni, a bacterium that causes food and water-borne disease (mainly diarrhea). The objectives are to 1) determine if healthy subjects develop short-term (\<6 month) protection to reinfection with C. jejuni; and 2) characterize the immune responses to C. jejuni infection. Information obtained will be used in development of a vaccine against Campylobacter infections. Volunteers will be screened for eligibility within 60 days prior to enrollment. Screening will include obtaining informed consent prior to any study procedure. This will be followed by medical history, physical examination, review of current medications, blood samples for safety labs (WBC, Hct, Hgb, platelet count; chemistry panel; screening for HIV, HLA-B27, HBV, and HCV); urine pregnancy testing for females. Stool will be tested for infection. Eligible volunteers will be enrolled in the study and admitted to the GCRC on Day -1. They will drink a measured dose of C. jejuni on Day 0, and followed for approximately 9 inpatient days, during which time the investigators expect at least 75% to develop a diarrheal illness, which will be promptly treated with replacement fluids (oral or IV, as indicated) and antibiotics. During the inpatient period, subjects will be assessed for any adverse events, and blood and stool specimens will be analyzed for markers of infection and markers of immune response. Subjects must have resolved or resolving symptoms and two negative stool cultures ≥12 hours apart to be eligible for discharge, and will be seen in outpatient follow-up at 21, 28, 35, 60, and 90 days for additional AE assessments and blood and stool analysis. Eight subjects will return for redosing approximately 98 days after the initial dose, with the same inpatient and outpatient follow-up as above. Few or none should develop a diarrheal illness. Four naïve (previously unexposed) subjects will also receive the dose on Day 98 to confirm a 75% illness rate with this dose. They will be followed as the initial group was. All participants will be assessed by phone 6 months after the final dose they received.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
September 2011
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
January 2010
Date type not reportedThis date has not been verified as actual or estimated.
January 12, 2010
Actual (reported)January 13, 2010
Actual (reported)December 2010
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
September 2011
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Development of campylobacteriosis in response to a dose of Campylobacter jejuni strain CG8421
10 days
Immunologic responses to dosing with Campylobacter jejuni strain CG8421
9 months
Will receive one dose of Campylobacter jejuni strain CG8421 at day 0 and a second dose at approximately day 98.
Will receive one dose of Campylobacter jejuni strain CG8421
Single oral dose of Campylobacter jejuni strain CG8421 in sodium bicarbonate buffer
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Navy Medical Research Center
Silver Spring, Maryland, 20910, United States
University of Vermont
Burlington, Vermont, 05401, United States
Kirkpatrick BD, Lyon CE, Porter CK, Maue AC, Guerry P, Pierce KK, Carmolli MP, Riddle MS, Larsson CJ, Hawk D, Dill EA, Fingar A, Poly F, Fimlaid KA, Hoq F, Tribble DR. Lack of homologous protection against Campylobacter jejuni CG8421 in a human challenge model. Clin Infect Dis. 2013 Oct;57(8):1106-13. doi: 10.1093/cid/cit454. Epub 2013 Jul 9.
Beth Kirkpatrick, MD
University of Vermont
David Tribble, MD
Navy Medical Research Center
First Submitted
January 12, 2010
First Posted
January 13, 2010
Study Start
January 2010
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
December 2010
Estimated (date passed)Contact the study team to confirm eligibility.
This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
September 2011
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Last Updated
January 13, 2010
Record last verified: 2010-01
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: